PRIMARY SCLEROSING CHOLANGITIS
Clinical trials for PRIMARY SCLEROSING CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY SCLEROSING CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare liver disease: elafibranor trial underway
Disease control OngoingThis study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also look at blood tests to see if…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
Gluten-Free diet shows promise for liver and gut disease
Disease control OngoingThis study explores whether avoiding gluten can slow disease progression and ease symptoms in people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in lab results, gut bacteria, and quality of life in 60 adults over …
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: NA • Sponsor: Institute for Clinical and Experimental Medicine • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New hope for rare liver disease: experimental drug CS0159 enters phase 2 trial
Disease control OngoingThis study tests a new drug called CS0159 in 50 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if the drug is safe and can improve liver health by lowering certain liver enzyme levels. Participants will receive either CS0159 or a placeb…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Could a common cholesterol drug slow a rare liver disease?
Disease control OngoingThis study tests whether taking simvastatin daily for 5 years can improve survival and reduce serious complications like liver failure, cancer, or bleeding in people with primary sclerosing cholangitis (PSC). About 560 adults with PSC will receive either simvastatin or a placebo.…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE3 • Sponsor: Annika Bergquist • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug offers hope for relentless itching in rare liver disease
Symptom relief OngoingThis study tests a medicine called volixibat to see if it can reduce severe itching caused by primary sclerosing cholangitis (PSC), a rare liver disease. About 182 people aged 12 and older with PSC-related itching will receive either volixibat or a placebo. The main goal is to me…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:05 UTC